Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II

Histopathology

Volumn 54, Issue 2, 2009, Pages 241-247

  Stockhammer, Florian ^a   Von Deimling, Andreas ^b   Van Landeghem, Frank K H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cystine glutamate antiporter; Loss of heterozygosity; Low grade glioma; SLC7A11

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE TRANSPORTER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CHROMOSOME 1P; CLINICAL ARTICLE; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AMINO ACID TRANSPORT SYSTEM X-AG; AMINO ACID TRANSPORT SYSTEM Y+; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 58649110606     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03153.x     Document Type: Article

References (44)

1. Kanner AA, Staugaitis SM, Castilla EA et al. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J. Neurosurg. 2006 104 542 550.
2. Kouwenhoven MC, Kros JM, French PJ et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur. J. Cancer 2006 42 2499 2503.
3. Wharton SB, Maltby E, Jellinek DA et al. Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol. 2007 113 119 127.
4. Chung WJ, Lyons SA, Nelson GM et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 2005 25 7101 7110.
5. Miura K, Ishii T, Sugita Y, Bannai S. Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress. Am. J. Physiol. 1992 262 (1 Pt 1 C50 C58.
6. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006 232 139 147.
7. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 1995 15 (3 Pt 1 1835 1853.
8. Rothstein JD, Martin L, Levey AI et al. Localization of neuronal and glial glutamate transporters. Neuron 1994 13 713 725.
9. Torp R, Danbolt NC, Babaie E et al. Differential expression of two glial glutamate transporters in the rat brain: an in situ hybridization study. Eur. J. Neurosci. 1994 6 936 942.
10. Shashidharan P, Huntley GW, Meyer T, Morrison JH, Plaitakis A. Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain. Brain Res. 1994 662 245 250.
11. Furuta A, Martin LJ, Lin CL, Dykes-Hoberg M, Rothstein JD. Cellular and synaptic localization of the neuronal glutamate transporters excitatory amino acid transporter 3 and 4. Neuroscience 1997 81 1031 1042.
12. Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005 64 10 14.
13. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998 4 844 847.
14. Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 1999 274 11455 11458.
15. Remmele W, Hildebrand U, Hienz HA et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch. 1986 409 127 147.
16. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960 20 37.
17. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 2001 195 72 79.
18. Moch H, Kononen T, Kallioniemi OP, Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001 8 14 20.
19. Reiner A, Spona J, Reiner G et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am. J. Pathol. 1986 125 443 449.
20. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 2005 65 1934 1940.
21. Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 1999 19 10767 10777.
22. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J. Neurooncol. 2000 47 11 22.
23. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J. Neurooncol. 2003 61 151 160.
24. Lewerenz J, Klein M, Methner A. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity. J. Neurochem. 2006 98 916 925.
25. Palos TP, Ramachandran B, Boado R, Howard BD. Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter. Brain Res. 1996 37 297 303.
26. Okuno S, Sato H, Kuriyama-Matsumura K et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 2003 88 951 956.
27. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005 65 7446 7454.
28. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 1998 90 1473 1479.
29. Weller M, Berger H, Hartmann C et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 2007 13 6933 6937.
30. Sontheimer H. Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci. 2003 26 543 549.
31. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001 7 1010 1015.
32. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994 35 1018 1034 discussion 1034-1035.
33. Nijjar TS, Simpson WJ, Gadalla T, McCartney M. Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984). Cancer 1993 71 4002 4006.
34. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J. Neurosurg. 1992 76 428 434.
35. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000 54 1442 1448.
36. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. [The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna]. Wien. Klin. Wochenschr. 2002 114 911 916.
37. Kim JY, Kanai Y, Chairoungdua A et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim. Biophys. Acta 2001 1512 335 344.
38. Louw DF, Bose R, Sima AA, Sutherland GR. Evidence for a high free radical state in low-grade astrocytomas. Neurosurgery 1997 41 1146 1150 discussion 1151.
39. Jefferies H, Coster J, Khalil A, Bot J, McCauley RD, Hall JC. Glutathione. ANZ J Surg 2003 73 517 522.
40. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005 64 479 489.
41. Mueller W, Hartmann C, Hoffmann A et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am. J. Pathol. 2002 161 313 319.
42. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001 15 1633 1640.
43. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 2003 23 4571 4579.
44. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007 67 9463 9471.